Hemab Therapeutics (NASDAQ:COAG) Announces Earnings Results, Misses Expectations By $0.17 EPS

Hemab Therapeutics (NASDAQ:COAG) released its quarterly earnings results on Tuesday. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17), FiscalAI reports.

Hemab Therapeutics Trading Up 1.2%

COAG stock traded up $0.65 during midday trading on Thursday, hitting $54.13. The company’s stock had a trading volume of 24,203 shares, compared to its average volume of 318,857. The stock has a market cap of $2.53 billion and a PE ratio of -2.26. The company’s 50-day moving average is $38.01. Hemab Therapeutics has a 1 year low of $23.00 and a 1 year high of $54.74.

Insider Activity at Hemab Therapeutics

In related news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The shares were bought at an average cost of $24.98 per share, with a total value of $1,536,844.54. Following the acquisition, the insider owned 6,444,637 shares of the company’s stock, valued at $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders acquired 72,467 shares of company stock worth $1,809,595.

Trending Headlines about Hemab Therapeutics

Here are the key news stories impacting Hemab Therapeutics this week:

• Positive Sentiment: HC Wainwright improved several longer-term loss estimates: FY2028 EPS to $(3.62) from $(3.63), FY2029 EPS to $(3.60) from $(3.89), and FY2030 EPS to $(2.04) from $(2.44). The firm also narrowed its expected Q4 2026 loss to $(0.57) per share from $(0.60), signaling somewhat better anticipated financial performance.
• Positive Sentiment: The $60 price target and Buy rating provide a favorable analyst outlook for Hemab’s development and commercial potential, which can help support investor sentiment.
• Neutral Sentiment: Hemab reported its second-quarter 2026 financial results and provided a corporate update. The available report headline does not include specific financial or pipeline details, so the direct market impact cannot be assessed from the information provided. Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• Negative Sentiment: HC Wainwright modestly lowered its FY2026 EPS forecast to $(3.19) from $(3.12), indicating a slightly larger expected loss in that year. Hemab remains unprofitable, with the current-year consensus estimate at $(2.89) EPS.

Wall Street Analyst Weigh In

COAG has been the subject of several recent analyst reports. HC Wainwright upped their target price on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday. Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. The Goldman Sachs Group began coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price target on the stock. Jefferies Financial Group upped their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.40.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.